Safely Transition Patients Taking the New Nebulized Med Yupelri at Home

April 2019

You'll see Yupelri (yoo-PEL-ree, revefenacin), the first ONCE-daily nebulized long-acting muscarinic antagonist (LAMA) for COPD.

It will have an edge over TWICE-daily Lonhala Magnair (glycopyrrolate)...the only other nebulized LAMA.

Yupelri is given via a standard nebulizer. Lonhala requires its own Magnair nebulizer...which can't be used to nebulize other meds.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Surgery Tailor Enhanced Recovery After Surgery (ERAS) Protocols to Your Hospital's Needs
Anticoagulants Add DOACs to Your List of Options for Treating HIT
Infectious Diseases Update Your Colistin and Polymyxin B Protocols
Measles Be Prepared if a Measles Outbreak Brings Patients to Your Hospital
Edema Look for Medication Causes of Peripheral Edema
Anxiety Think of Buspirone as a Second-Line Option for Managing Anxiety
Epinephrine Be Aware of Differences Between Symjepi and Epinephrine Auto-Injectors
Hyperkalemia Know When to Choose One Potassium Binder Over Another
New Drugs Safely Transition Patients Taking the New Nebulized Med Yupelri at Home